General information | |
ACovPid: | ACoVP100293 |
Trivial Name: | P21R8 |
Amino Acids Sequence: | LDLTYEMLSLQ-RPA-VVK-RPA-LNESY |
Length: | |
C-Terminal Modification: | None |
N-Terminal Modification: | None |
Chemical Modification: | RPA: (R)-2-(4-pentenyl) alanine;   |
Peptide Source: | The Middle East respiratory syndrome coronavirus (MERS-CoV) : |
Source Description: | S2 subunit of spike (S) protein of MERS-CoV |
Against Virus: | |
Inhibition Value Type: | EC50 |
Inhibitory Effect: | 16.3 ± 1.1 |
Inhibitory Unit: | µM |
Target Domain Name: | |
Assay: | Cell–cell fusion assay |
Assay Description: | MERS-CoV S protein-mediated cell–cell fusion was assessed, as described previously.(PMID: 25331705, 25451066) In brief, 293T cells expressing MERS-CoV S protein and enhanced GFP (EGFP) were used as the effector cells (293T/MERS/EGFP), and Huh-7 cells expressing the MERS-CoV receptor DPP4 were used as the target cells. 293T/EGFP cells, which express only EGFP, were used as negative control cells. Huh-7 cells were plated in a 96-well plate (5 × 10^4 per well) and cultured at 37 °C for 5 h. Inhibitors at the indicated concentrations were then added, followed by the addition of 293T/MERS/EGFP cells or 293T/EGFP cells (1 × 10^4 per well). After coculture at 37 °C for 4 h, the 293T/MERS/EGFP cells and 293T/EGFP cells fused or unfused with Huh-7 cells were counted under an inverted fluorescence microscope (Nikon Eclipse Ti–S). |
Anti-CoV activity in vivo: | |
Reference: | 29442512 |
Comment: | |
3D structure: | |
Structure Experiment Verified: | |
Similar Peptides: | ACoVP100284   ACoVP100295   ACoVP100283   ACoVP100294   ACoVP100296 |